|
General Information
|
|
|
Product
|
ASXL3 Peptide
|
|
Description
|
Antigenic Blocking Peptide Putative Polycomb group protein ASXL3 Antibody
|
|
Verified Applications
|
Immunodepletion, Immunocompetition
|
|
Peptide Description
|
Synthetic peptide taken within amino acid region 2100-2150 on human Putative Polycomb group protein ASXL3.
|
|
Physical Properties
|
|
|
Quantity
|
250 µg
|
|
Volume
|
100 µl
|
|
Form
|
Antigenic Blocking Peptide
|
|
Storage
|
-20⁰C for long term storage
|
|
Application Protocol
|
|
Competition/Depletion assay
|
Refer to competition assay protocol
|
|
Protein
|
|
Uniprot #
|
Q8C4A5
|
|
Overview
|
Putative Polycomb group (PcG) protein. PcG proteins act by forming multiprotein complexes, which are required to maintain the transcriptionally repressive state of homeotic genes throughout development. PcG proteins are not required to initiate repression, but to maintain it during later stages of development. They probably act via methylation of histones, rendering chromatin heritably changed in its expressibility.
|
|
Molecular Function
|
chromatin binding
DNA binding
metal ion binding
peroxisome proliferator activated receptor binding
|
|
Subcellular Location
|
Nuceus
|
|
Structure
|
Zinc-finger
|
|
Alternative Nomenclature
|
Additional sex combs-like protein 3
ASXL3
KIAA1713
Putative Polycomb group protein ASXL3
|
|
|
|
ASXL3 Antibody
ASXL3 Antibody BIOTIN
ASXL3 Antibody FITC
ASXL3 Positive Control
